vs
ENCORE CAPITAL GROUP INC（ECPG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ENCORE CAPITAL GROUP INC的1.6倍（$772.1M vs $473.6M），ENCORE CAPITAL GROUP INC净利率更高（16.2% vs 12.7%，领先3.4%），ENCORE CAPITAL GROUP INC同比增速更快（78.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $126.9M），过去两年ENCORE CAPITAL GROUP INC的营收复合增速更高（20.1% vs 9.0%）
安可资本集团是一家总部位于美国圣地亚哥的公开上市不良债权收购机构，业务覆盖美国全境，公司股票在纳斯达克全球精选市场上市交易，同时被纳入罗素2000、标普小盘600、威尔希尔4500等多个指数成分股。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ECPG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$473.6M
营收增速更快
ECPG
高出72.4%
5.9%
净利率更高
ECPG
高出3.4%
12.7%
自由现金流更多
RVTY
多$34.9M
$126.9M
两年增速更快
ECPG
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $473.6M | $772.1M |
| 净利润 | $76.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 36.6% | 14.5% |
| 净利率 | 16.2% | 12.7% |
| 营收同比 | 78.3% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $3.32 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ECPGRVTY
| Q4 25 | $473.6M | $772.1M | ||
| Q3 25 | $460.4M | $698.9M | ||
| Q2 25 | $442.1M | $720.3M | ||
| Q1 25 | $392.8M | $664.8M | ||
| Q4 24 | $265.6M | $729.4M | ||
| Q3 24 | $367.1M | $684.0M | ||
| Q2 24 | $355.3M | $691.7M | ||
| Q1 24 | $328.4M | $649.9M |
净利润ECPGRVTY
| Q4 25 | $76.7M | $98.4M | ||
| Q3 25 | $74.7M | $46.7M | ||
| Q2 25 | $58.7M | $53.9M | ||
| Q1 25 | $46.8M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $30.6M | $94.4M | ||
| Q2 24 | $32.2M | $55.4M | ||
| Q1 24 | $23.2M | $26.0M |
毛利率ECPGRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ECPGRVTY
| Q4 25 | 36.6% | 14.5% | ||
| Q3 25 | 37.6% | 11.7% | ||
| Q2 25 | 34.1% | 12.6% | ||
| Q1 25 | 32.9% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 28.9% | 14.3% | ||
| Q2 24 | 28.7% | 12.4% | ||
| Q1 24 | 25.5% | 6.8% |
净利率ECPGRVTY
| Q4 25 | 16.2% | 12.7% | ||
| Q3 25 | 16.2% | 6.7% | ||
| Q2 25 | 13.3% | 7.5% | ||
| Q1 25 | 11.9% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 8.3% | 13.8% | ||
| Q2 24 | 9.1% | 8.0% | ||
| Q1 24 | 7.1% | 4.0% |
每股收益（稀释后）ECPGRVTY
| Q4 25 | $3.32 | $0.86 | ||
| Q3 25 | $3.17 | $0.40 | ||
| Q2 25 | $2.49 | $0.46 | ||
| Q1 25 | $1.93 | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | $1.26 | $0.77 | ||
| Q2 24 | $1.34 | $0.45 | ||
| Q1 24 | $0.95 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.8M | $919.9M |
| 总债务越低越好 | $4.0B | — |
| 股东权益账面价值 | $976.8M | $7.3B |
| 总资产 | $5.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 4.13× | — |
8季度趋势，按日历期对齐
现金及短期投资ECPGRVTY
| Q4 25 | $156.8M | $919.9M | ||
| Q3 25 | $172.5M | $931.4M | ||
| Q2 25 | $172.9M | $991.8M | ||
| Q1 25 | $187.1M | $1.1B | ||
| Q4 24 | $199.9M | $1.2B | ||
| Q3 24 | $247.4M | $1.2B | ||
| Q2 24 | $250.6M | $2.0B | ||
| Q1 24 | $173.0M | $1.7B |
总债务ECPGRVTY
| Q4 25 | $4.0B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ECPGRVTY
| Q4 25 | $976.8M | $7.3B | ||
| Q3 25 | $952.9M | $7.4B | ||
| Q2 25 | $896.0M | $7.6B | ||
| Q1 25 | $819.1M | $7.6B | ||
| Q4 24 | $767.3M | $7.7B | ||
| Q3 24 | $1.0B | $7.9B | ||
| Q2 24 | $988.1M | $7.9B | ||
| Q1 24 | $953.9M | $7.8B |
总资产ECPGRVTY
| Q4 25 | $5.3B | $12.2B | ||
| Q3 25 | $5.3B | $12.1B | ||
| Q2 25 | $5.2B | $12.4B | ||
| Q1 25 | $5.0B | $12.4B | ||
| Q4 24 | $4.8B | $12.4B | ||
| Q3 24 | $5.0B | $12.8B | ||
| Q2 24 | $4.8B | $13.4B | ||
| Q1 24 | $4.7B | $13.4B |
负债/权益比ECPGRVTY
| Q4 25 | 4.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.83× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $153.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $126.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 26.8% | 21.0% |
| 资本支出强度资本支出/营收 | 5.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.00× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $244.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ECPGRVTY
| Q4 25 | $153.2M | $182.0M | ||
| Q3 25 | $81.6M | $138.5M | ||
| Q2 25 | $9.5M | $134.3M | ||
| Q1 25 | $45.3M | $128.2M | ||
| Q4 24 | $156.2M | $174.2M | ||
| Q3 24 | $45.9M | $147.9M | ||
| Q2 24 | $35.7M | $158.6M | ||
| Q1 24 | $51.0M | $147.6M |
自由现金流ECPGRVTY
| Q4 25 | $126.9M | $161.8M | ||
| Q3 25 | $75.6M | $120.0M | ||
| Q2 25 | $3.2M | $115.5M | ||
| Q1 25 | $38.3M | $112.2M | ||
| Q4 24 | $127.2M | $149.8M | ||
| Q3 24 | $39.7M | $125.6M | ||
| Q2 24 | $28.3M | $136.6M | ||
| Q1 24 | $44.1M | $129.7M |
自由现金流率ECPGRVTY
| Q4 25 | 26.8% | 21.0% | ||
| Q3 25 | 16.4% | 17.2% | ||
| Q2 25 | 0.7% | 16.0% | ||
| Q1 25 | 9.7% | 16.9% | ||
| Q4 24 | 47.9% | 20.5% | ||
| Q3 24 | 10.8% | 18.4% | ||
| Q2 24 | 8.0% | 19.7% | ||
| Q1 24 | 13.4% | 20.0% |
资本支出强度ECPGRVTY
| Q4 25 | 5.5% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 10.9% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 2.1% | 2.7% |
现金转化率ECPGRVTY
| Q4 25 | 2.00× | 1.85× | ||
| Q3 25 | 1.09× | 2.97× | ||
| Q2 25 | 0.16× | 2.49× | ||
| Q1 25 | 0.97× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.50× | 1.57× | ||
| Q2 24 | 1.11× | 2.87× | ||
| Q1 24 | 2.19× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ECPG
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
